Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

774 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe.
Pursuing Later Treatment Options II (PLATO II) project team; Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Group; Nakagawa F, Lodwick R, Costagliola D, van Sighem A, Torti C, Podzamczer D, Mocroft A, Ledergerber B, Dorrucci M, Cozzi-Lepri A, Jansen K, Masquelier B, García F, De Wit S, Stephan C, Obel N, Fätkenhaeuer G, Castagna A, Sambatakou H, Mussini C, Ghosn J, Zangerle R, Duval X, Meyer L, Perez-Hoyos S, Fabre Colin C, Kjaer J, Chene G, Grarup J, Phillips A. Pursuing Later Treatment Options II (PLATO II) project team, et al. Among authors: chene g. J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):294-9. doi: 10.1097/QAI.0b013e31823fe66b. J Acquir Immune Defic Syndr. 2012. PMID: 22083070
Impact of discontinuation of initial protease inhibitor therapy on further virological response in a cohort of human immunodeficiency virus-infected patients.
Le Moing V, Chêne G, Leport C, Lewden C, Duran S, Garré M, Masquelier B, Dupon M, Raffi F; Antiprotéases Cohorte (APROCO) Study Group. Le Moing V, et al. Among authors: chene g. Clin Infect Dis. 2002 Jan 15;34(2):239-47. doi: 10.1086/324354. Epub 2001 Dec 4. Clin Infect Dis. 2002. PMID: 11740714
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.
Egger M, May M, Chêne G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, D'Arminio Monforte A, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne JA; ART Cohort Collaboration. Egger M, et al. Among authors: chene g. Lancet. 2002 Jul 13;360(9327):119-29. doi: 10.1016/s0140-6736(02)09411-4. Lancet. 2002. PMID: 12126821
Bivariate linear mixed models using SAS proc MIXED.
Thiébaut R, Jacqmin-Gadda H, Chêne G, Leport C, Commenges D. Thiébaut R, et al. Among authors: chene g. Comput Methods Programs Biomed. 2002 Nov;69(3):249-56. doi: 10.1016/s0169-2607(02)00017-2. Comput Methods Programs Biomed. 2002. PMID: 12204452 Free article.
Health-related quality of life after 1 year of highly active antiretroviral therapy.
Carrieri P, Spire B, Duran S, Katlama C, Peyramond D, François C, Chêne G, Lang JM, Moatti JP, Leport C; APROCO Study Group. Carrieri P, et al. Among authors: chene g. J Acquir Immune Defic Syndr. 2003 Jan 1;32(1):38-47. doi: 10.1097/00126334-200301010-00006. J Acquir Immune Defic Syndr. 2003. PMID: 12514412 Clinical Trial.
[Causes of death in HIV-infected French drug users, 1995-2000].
Lewden C, Bonnet F, Bevilacqua S, Heripret L, May T, Morlat P, Jougla E, Dabis F, Chêne G, Salmon D; Groupe d'Epidémiologie Clinique du SIDA en Aquitaine; Groupe "Mortalité 2000". Lewden C, et al. Among authors: chene g. Ann Med Interne (Paris). 2002 Nov;153(7 Suppl):2S4-10. Ann Med Interne (Paris). 2002. PMID: 12518077 French.
774 results